Why invest in Nemysis?
We focus on markets with large, unmet needs and poor therapy options available:
An estimated 80 million people globally suffer from Celiac Disease (prevalence of 1%) and about 480 million from Non-Celiac Gluten Sensitivity (prevalence of 6-8%), representing a market opportunity of about €3 billion and €15 billion respectively. No viable preventative treatment is currently available for these conditions other than management through a gluten free diet and E40 represents a breakthrough innovation in the field.
Almost 2 billion people globally suffer from some form of iron deficiency, (prevalence of 24%) representing a market opportunity of €13.5 billion. Current treatment options are sub-optimal, with adverse side effects negatively impacting compliance, clearly differentiating IHAT as the oral iron supplement treatment of choice, in particular in those with pre-existing inflammatory conditions, thanks to its effective iron repletion and its innovative mechanism of absorption and associated improved tolerability and safety profile.
We have a de-risked, high success Product Strategy:
- Robust IP protection in all major markets
- Three-pronged regulatory pathway, accessing shorter, more cost effective routes to market as well as increasing access, including GRAS notification (US)/Novel Food Procedure (EU)
- Agile, networked infrastructure, minimising overhead costs
- Partnership with distribution partners internationally, accelerating market entry and penetration.
Nemysis has a well-established presence in the gut-mediated disorder research space and is poised for strong future growth in this area. This has been recognised by both:
- successful award of multi-million-Euro funding through competitive European and US grant awards; and
- previous successful rounds, supported by industry participants based on their understanding and support for our strategy
We are now seeking investment partners for our final round to fully finance completion of the final development step of E40 to market in Europe, as well as grow and drive our business development and commercialisation, achieving positive free cashflow.
We are perfectly positioned to continue to grow Nemysis following our transition to a commercial company, leveraging our people and products and working with our investors to continue to make a real difference in the gut-mediated disorder marketplace.
Marco Cartolari | Chief Operating Officer
Partnering
What makes us stand out in our chosen markets?
Nemysis is built on an enviable product and research pipeline, and is growing fast. We have three technology platforms in various stages of development and were the first company to file our nano iron [IHAT nano-ferric (III)] for approval by the European Food Safety Authority in 2019. With several possible routes to market, from novel food supplement and GRAS Notification (in the U.S.) to medical device and prescription drug, we have short, medium, and long-term returns-on-investment outlook, which we deem very attractive for a variety of commercial and investment partners.
We come from a background deeply rooted in pharmaceuticals and healthcare.
With a lean leadership team bringing diverse and complementary skills, we have a proven and successful track record in speciality pharma and are small enough to be agile and tough enough to take key decisions in a timely fashion. Our highly experienced and talented Board of Directors are hands on which gives us the ability to act quickly to capitalise on development opportunities.
We are supported by a wide ranging and trusted Board of Scientific and Clinical Advisors who are leaders in their field. Together we are able to connect innovative products with disease areas which have large commercial potential and unmet patient needs.
If you are interested in finding out more, please contact Danilo Casadei Massari, our Chairman at casadei-massari@nemysisltd.com or Marco Cartolari, our COO at cartolari@nemysisltd.com.
Why Partner with Nemysis?
Nemysis is built on success, with an enviable product and research portfolio. We work and grow fast, whilst maintaining quality in all we do. We do this through forming synergistic and collaborative partnerships that bring value to both parties. If you are interested in working with us to bring our products to those who need them, we would be delighted to hear from you.
If you would like to start a conversation please contact our COO Marco Cartolari at cartolari@nemysisltd.com